news
02-11-2013, 02:32 AM
The request by the F.D.A. for more data on the heart risks of a diabetes drug will delay an important product for Novo Nordisk of Denmark.http://rss.nytimes.com/c/34625/f/642562/s/286e9c05/mf.gif
More... (http://www.nytimes.com/2013/02/11/business/fda-wants-more-tests-on-a-novo-nordisk-insulin-tresiba.html?partner=rss&emc=rss)
More... (http://www.nytimes.com/2013/02/11/business/fda-wants-more-tests-on-a-novo-nordisk-insulin-tresiba.html?partner=rss&emc=rss)